<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17243" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Adrenoleukodystrophy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Alsaleem</surname>
            <given-names>Mahdi</given-names>
          </name>
          <aff>University of Kansas /Children's Mercy Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Haq</surname>
            <given-names>Nowreen</given-names>
          </name>
          <aff>University of Maryland Medical Systems and George Washington Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadeh</surname>
            <given-names>Lina</given-names>
          </name>
          <aff>Children's Mercy Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mahdi Alsaleem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nowreen Haq declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lina Saadeh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17243.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Adrenoleukodystrophy is a rare genetic peroxisomal disorder characterized by the abnormal metabolism of very long-chain fatty acids (VLCFAs) due to mutations in the <italic toggle="yes">ABCD1</italic> gene.&#x000a0;This leads to the accumulation of VLCFAs, particularly affecting the brain, spinal cord, adrenal glands, and testes. The condition is classified into various subtypes based on inheritance patterns, clinical presentation, age of onset, and affected organs.&#x000a0;Diagnosis typically involves clinical suspicion prompted by neurological symptoms and biochemical testing showing elevated VLCFAs. Genetic confirmation through DNA analysis of <italic toggle="yes">ABCD1</italic> gene mutations is crucial for a definitive diagnosis.</p>
        <p>Management focuses on early detection through newborn screening programs in some regions, followed by regular monitoring of VLCFA levels. Symptoms typically include progressive neurological dysfunction and adrenal insufficiency, which is managed with glucocorticoid and mineralocorticoid replacement therapies. Hematopoietic stem cell transplantation (HSCT) remains the primary therapeutic option for early-stage adrenoleukodystrophy, offering the best chance to halt disease progression and improve outcomes. Despite these interventions, the prognosis is generally poor, with most patients developing severe neurological disabilities and a shortened lifespan.&#x000a0;This activity reviews the pathophysiology, clinical manifestations, and genetic basis of adrenoleukodystrophy and&#x000a0;provides clinicians with a comprehensive understanding of&#x000a0;the condition.&#x000a0;This activity also highlights the crucial role of the multidisciplinary healthcare team in recognizing the symptoms of progressive neurological dysfunction and adrenal insufficiency through early diagnosis and in becoming familiar with current management strategies. Additionally, this activity will offer clinicians insights into the therapeutic potential of HSCT for managing early-stage adrenoleukodystrophy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify early signs and symptoms of adrenoleukodystrophy to facilitate timely diagnosis and intervention.&#x000a0;</p></list-item><list-item><p>Implement appropriate diagnostic tests, including very long-chain fatty acids measurement and genetic analysis, to confirm adrenoleukodystrophy and guide treatment.</p></list-item><list-item><p>Apply current evidence-based guidelines for the management of adrenoleukodystrophy, including glucocorticoid and mineralocorticoid replacement therapies.</p></list-item><list-item><p>Collaborate with a multidisciplinary healthcare team, including neurologists, endocrinologists, and geneticists, to provide comprehensive care for adrenoleukodystrophy patients.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17243&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17243">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17243.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Adrenoleukodystrophy is a rare genetic condition characterized by impaired metabolism of very long-chain fatty acids (VLCFAs), leading to their accumulation in various tissues, particularly the nervous system and adrenal glands. This accumulation arises from mutations in the&#x000a0;<italic toggle="yes">ABCD1</italic>&#x000a0;gene, which encodes a peroxisomal membrane protein involved in VLCFA transport and degradation.&#x000a0;Although earlier reports in the 1900s described clinical presentations suggestive of this disease, the terminology and pathophysiology were&#x000a0;not clarified until the 1970s.<xref ref-type="bibr" rid="article-17243.r1">[1]</xref> The brain, spinal cord, adrenal glands, and testes are the most commonly affected organs.&#x000a0;Clinical manifestations of adrenoleukodystrophy vary widely but usually include the combination of progressive neurological dysfunction&#x000a0;and adrenal insufficiency.<xref ref-type="bibr" rid="article-17243.r2">[2]</xref></p>
      </sec>
      <sec id="article-17243.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Adrenoleukodystrophy is usually X-linked (X-ALD) and caused by over 2700 known mutations in the&#x000a0;<italic toggle="yes">ABCD1</italic>&#x000a0;gene mutations.<xref ref-type="bibr" rid="article-17243.r3">[3]</xref> The&#x000a0;<italic toggle="yes">ABCD1</italic>&#x000a0;gene plays a significant role&#x000a0;in the&#x000a0;VLCFA transport system into peroxisomes, where VLCFAs can undergo further metabolism. Mutations in the&#x000a0;<italic toggle="yes">ABCD1</italic>&#x000a0;gene product interfere with this process, leading to the abnormal accumulation of VLCFAs in various body organs and interfering with their normal physiological functions.</p>
        <p>A similar peroxisomal syndrome, Zellweger spectrum disorder, is caused by mutations in the PTS1 receptor, PXR, or any of the many identified <italic toggle="yes">PEX</italic> genes. The&#x000a0;<italic toggle="yes">PEX</italic> genes are involved in the formation and function of peroxisomes. One of the Zellweger spectrum disorders is neonatal adrenoleukodystrophy,&#x000a0;which has an earlier and more severe presentation than other forms of ALD.<xref ref-type="bibr" rid="article-17243.r2">[2]</xref><xref ref-type="bibr" rid="article-17243.r4">[4]</xref></p>
        <p>Four main subtypes of adrenoleukodystrophy are described based on the organs affected and the age at presentation&#x02014;neonatal, childhood cerebral, adrenomyeloneuropathy, and adrenal insufficiency.</p>
      </sec>
      <sec id="article-17243.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Adrenoleukodystrophy is the most common genetic disorder affecting peroxisomes, with an estimated prevalence of 1 in 14,700.<xref ref-type="bibr" rid="article-17243.r3">[3]</xref> The disease incidence is higher in patients of Latino or African descent.<xref ref-type="bibr" rid="article-17243.r5">[5]</xref>&#x000a0;Neonatal adrenoleukodystrophy has a prevalence of 1 in 50,000.<xref ref-type="bibr" rid="article-17243.r6">[6]</xref></p>
        <p>
<bold>Prevalence</bold>
</p>
        <p>Adrenoleukodystrophy affects approximately 1 in 20,000 to 1 in 50,000 individuals globally.</p>
        <p>
<bold>Sex Distribution</bold>
</p>
        <p>Adrenoleukodystrophy primarily affects males due to its X-linked recessive inheritance. Females are typically carriers and may have mild or no symptoms.</p>
        <p>
<bold>Age of Onset</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Childhood cerebral adrenoleukodystrophy: Presents between ages 4 and 10, with rapid progression.</p>
          </list-item>
          <list-item>
            <p>Adolescent and adult cerebral adrenoleukodystrophy: Milder form that appears during adolescence or adulthood, with slower progression.</p>
          </list-item>
          <list-item>
            <p>Adrenomyeloneuropathy: Manifests in adulthood (between ages 20 and 40 in men and by age 65 in women) with gradual motor and sensory deficits.<xref ref-type="bibr" rid="article-17243.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Geographic and Ethnic Distribution</bold>
</p>
        <p>Adrenoleukodystrophy is found worldwide and affects all ethnic groups. Prevalence varies based on genetic factors and diagnostic capabilities.</p>
        <p>
<bold>Carrier Frequency</bold>
</p>
        <p>Approximately 1 in 17,000 females are carriers of adrenoleukodystrophy.</p>
        <p>
<bold>Risk Factors and Genetic Considerations</bold>
</p>
        <p>The primary risk factor is an inherited mutation in the <italic toggle="yes">ABCD1</italic> gene. A family history of adrenoleukodystrophy also increases the risk.</p>
        <p>
<bold>Public Health Implications</bold>
</p>
        <p>Early diagnosis through newborn screening is critical. Genetic counseling for families is essential. Increased awareness and research are needed to improve diagnostics, treatment, and support.</p>
      </sec>
      <sec id="article-17243.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Adrenoleukodystrophy is a rare genetic disorder that affects the nervous system and adrenal glands. Except for neonatal adrenoleukodystrophy, it is an X-linked recessive disorder, primarily affecting males, while females can be carriers. The pathophysiology is characterized by the accumulation of VLCFAs in tissues throughout the body, including the brain, spinal cord, and adrenal cortex.<xref ref-type="bibr" rid="article-17243.r7">[7]</xref>&#x000a0;Although adrenoleukodystrophy is linked to mutations in the&#x000a0;<italic toggle="yes">ABCD1</italic> and <italic toggle="yes">PEX</italic>&#x000a0;genes, these mutations do not fully account for the clinical syndromes, suggesting that other modifier genes, epigenetic factors, and environmental influences likely contribute as well.<xref ref-type="bibr" rid="article-17243.r8">[8]</xref></p>
        <p>
<bold>Key Aspects of Adrenoleukodystrophy Pathophysiology</bold>
</p>
        <p><bold>Genetic mutation:</bold> The disorder is caused by mutations in the <italic toggle="yes">ABCD1</italic> gene, which is located on the X chromosome. This gene encodes the adrenoleukodystrophy protein (ALDP), which is involved in transporting VLCFAs into peroxisomes for degradation.</p>
        <p><bold>VLCFA accumulation:</bold> Due to defective ALDP, VLCFAs cannot be properly transported into peroxisomes, leading to their accumulation in the body. Elevated VLCFA levels are toxic to cells, particularly affecting myelin, the protective sheath around nerve fibers in the central nervous system.</p>
        <p><bold>Demyelination:</bold> The accumulation of VLCFAs leads to progressive demyelination, where the myelin sheath is damaged and destroyed. This disruption severely impairs the conduction of nerve impulses, resulting in neurological symptoms.</p>
        <p><bold>Inflammatory response:</bold> The breakdown of myelin triggers an inflammatory response in the brain, which exacerbates the damage. The immune system's attack on the myelin leads to further neurological decline.</p>
        <p><bold>Adrenal insufficiency:</bold> VLCFAs also accumulate in the adrenal cortex, impairing its ability to produce adrenal hormones such as cortisol and aldosterone. This results in adrenal insufficiency, leading to symptoms such as fatigue, weight loss, and skin changes.</p>
      </sec>
      <sec id="article-17243.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>On gross examination, affected adrenal glands appear small and atrophied. Histological findings show nodular swelling primarily affecting the zona fasciculata and zona reticularis, with visible cellular vacuoles and clefts. The medulla is typically spared and appears normal.<xref ref-type="bibr" rid="article-17243.r9">[9]</xref></p>
        <p>Central nervous system (CNS) pathological findings in adrenoleukodystrophy include symmetrical demyelination of the white matter, typically affecting the corpus callosum and occipitoparietal region. In severe cases, the spinal cord may also be involved. At the cellular level, swelling and vacuolization result from infiltrates of active inflammatory cells, such as macrophages and astrocytes. These changes lead to the loss of myelin sheaths, oligodendrocytes, and neuronal axons. Histological examination ultimately reveals dystrophic mineralization.<xref ref-type="bibr" rid="article-17243.r10">[10]</xref></p>
        <p>
<bold>Microscopic Examination</bold>
</p>
        <p><bold>Luxol fast blue staining:</bold> This technique identifies myelin by staining it blue. Areas of demyelination will appear as pale or unstained regions.</p>
        <p><bold>Periodic acid-Schiff staining:</bold> This stain highlights macrophages with accumulated myelin debris, which appear as magenta deposits.</p>
        <p><bold>Immunohistochemistry:</bold> This technique uses specific markers (such as myelin basic protein) and inflammatory cells (such as&#x000a0;CD68 for macrophages) to identify and characterize the cellular components involved in the pathological process.</p>
      </sec>
      <sec id="article-17243.s7" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>
<bold>Absorption</bold>
</p>
        <p>Small amounts of VLCFA are absorbed from the diet, but&#x000a0;they are primarily synthesized endogenously through the&#x000a0;ELOVL1 enzyme.<xref ref-type="bibr" rid="article-17243.r3">[3]</xref></p>
        <p>
<bold>Distribution</bold>
</p>
        <p>VLCFAs accumulate in the brain, adrenal glands, and peripheral nerves due to defective transport into peroxisomes.</p>
        <p>
<bold>Metabolism</bold>
</p>
        <p>The defect in the <italic toggle="yes">ABCD1</italic> gene impairs the peroxisomal beta-oxidation of VLCFAs, leading to their buildup.</p>
        <p>
<bold>Toxic Effects</bold>
</p>
        <p>Accumulated VLCFAs lead to demyelination, inflammation, and adrenal insufficiency. Increased oxidative stress also contributes to pathology.<xref ref-type="bibr" rid="article-17243.r3">[3]</xref></p>
        <p>
<bold>Excretion</bold>
</p>
        <p>Inefficient degradation and excretion result in their persistent VLCFA accumulation in tissues.</p>
        <p>Understanding these toxicokinetic processes is crucial for developing therapeutic strategies aimed at improving clinical symptoms.<xref ref-type="bibr" rid="article-17243.r7">[7]</xref></p>
      </sec>
      <sec id="article-17243.s8" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Clinical manifestations of adrenoleukodystrophy vary significantly based on disease severity and age at presentation. The condition is broadly categorized into neonatal adrenoleukodystrophy and X-ALD. Neonatal adrenoleukodystrophy may present immediately after birth, but some infants may exhibit only mild symptoms, potentially delaying diagnosis in these cases.</p>
        <p>Typical signs and symptoms of neonatal adrenoleukodystrophy include:<xref ref-type="bibr" rid="article-17243.r2">[2]</xref><xref ref-type="bibr" rid="article-17243.r7">[7]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Seizures, hypotonia, and hearing dysfunction</p>
          </list-item>
          <list-item>
            <p>Vision loss, cataracts, and optic nerve dysplasia</p>
          </list-item>
          <list-item>
            <p>Jaundice and hepatomegaly</p>
          </list-item>
          <list-item>
            <p>Failure to thrive and facial dysmorphism (such as hypertelorism and flat midface)&#x000a0;<xref ref-type="bibr" rid="article-17243.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>X-ALD&#x000a0;is classified into the following 3 main phenotypes based on the age at presentation and the organs affected:</p>
        <list list-type="bullet">
          <list-item>
            <p>Childhood cerebral adrenoleukodystrophy</p>
          </list-item>
          <list-item>
            <p>Addison disease</p>
          </list-item>
          <list-item>
            <p>Adrenomyeloneuropathy</p>
          </list-item>
        </list>
        <p>Childhood cerebral adrenoleukodystrophy typically presents between ages 3 and 10. The hallmark of this form is developmental regression, and it is characterized by progressive sensory and severe neurological deficits, which often lead to significant disability, coma, and eventually death. Some adults may also develop symptoms similar to those seen in childhood cerebral adrenoleukodystrophy.&#x000a0;</p>
        <p>Addison disease is characterized by adrenal gland dysfunction in X-ALD. This phenotype results from reduced production of aldosterone and cortisol, leading to manifestations such as hyponatremia, fatigue, hypotension, dehydration, hypoglycemia, and generalized weakness. Hyperpigmentation of the skin may also occur. Males with adrenoleukodystrophy have an 80% lifetime risk of developing adrenal insufficiency.<xref ref-type="bibr" rid="article-17243.r3">[3]</xref></p>
        <p>Adrenomyeloneuropathy is a milder spectrum of X-ALD. The typical age at presentation is usually in the third decade of life for men and post-menopausal for women, with initial symptoms often involving spinal cord dysfunction. Approximately 65% of women with this form will exhibit symptoms of adrenoleukodystrophy by age 65.<xref ref-type="bibr" rid="article-17243.r3">[3]</xref>&#x000a0;Most men who survive until adulthood have the adrenomyeloneuropathy form of adrenoleukodystrophy. This form is characterized by a chronic progressive axonopathy affecting the sensory and motor spinal cord tracts, leading to progressive spastic paraparesis, peripheral neuropathy, bowel and bladder sphincter dysfunction, and sexual dysfunction, sometimes accompanied by adrenal insufficiency. Involvement of the cerebellum can result in walking difficulties, ataxia, and unbalanced gait.<xref ref-type="bibr" rid="article-17243.r12">[12]</xref></p>
        <p>Female carriers of X-ALD may also develop&#x000a0;subtler symptoms, such as unsteady gait, neuropathy, and mild paresis. Involvement of the adrenal glands and cerebrum is rare.<xref ref-type="bibr" rid="article-17243.r13">[13]</xref></p>
      </sec>
      <sec id="article-17243.s9" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The evaluation of adrenoleukodystrophy begins with considering the typical clinical presentation, characteristics, symptoms, signs, and suggestive family history. Several states have introduced newborn screening tests to identify infants with X-ALD. Including X-ALD in newborn screening programs helps identify affected newborns early, allowing for intervention before symptoms develop. Currently, approximately 30 states have implemented newborn screening programs for X-ALD.<xref ref-type="bibr" rid="article-17243.r7">[7]</xref><xref ref-type="bibr" rid="article-17243.r14">[14]</xref></p>
        <p>Laboratory workup may show abnormal liver function and a reduced response to adrenocorticotropic hormone administration. More specific indicators of adrenoleukodystrophy include elevated concentrations of VLCFAs in plasma, skin fibroblasts, and amniocytes.<xref ref-type="bibr" rid="article-17243.r3">[3]</xref>&#x000a0;Although increased VLCFA levels are strongly indicative of adrenoleukodystrophy, the degree of elevation does not necessarily correlate with disease type or severity.<xref ref-type="bibr" rid="article-17243.r15">[15]</xref> Additional findings may include decreased plasmalogen levels in red blood cells and increased concentrations of pipecolic and phytanic acids in both plasma and fibroblasts.<xref ref-type="bibr" rid="article-17243.r16">[16]</xref></p>
        <p>Magnetic resonance imaging (MRI) of the brain is crucial for the evaluation of adrenoleukodystrophy. Typical MRI findings include a white matter demyelination pattern, microgyria, and germinolytic cysts in the caudothalamic groove. Further genetic testing to identify the specific mutation causing the disorder is recommended to confirm the diagnosis.<xref ref-type="bibr" rid="article-17243.r17">[17]</xref></p>
      </sec>
      <sec id="article-17243.s10" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Adrenoleukodystrophy has no effective cure. Supportive care, including optimizing nutrition, occupational therapy, and respiratory support, can help alleviate some of the severe consequences of the disorder but typically does not significantly impact survival or long-term outcomes. Corticosteroid and mineralocorticoid replacement therapy is recommended for patients with impaired adrenal gland function. Some studies report that allogeneic hematopoietic stem cell transplantation (HSCT) can halt cerebral demyelination if performed before advanced brain disease develops, highlighting the importance of early screening for at-risk babies.<xref ref-type="bibr" rid="article-17243.r3">[3]</xref><xref ref-type="bibr" rid="article-17243.r18">[18]</xref>&#x000a0;Gene therapy trials using autologous stem cell transplants have shown short-term improvements without the significant risks of HSCT.<xref ref-type="bibr" rid="article-17243.r7">[7]</xref><xref ref-type="bibr" rid="article-17243.r19">[19]</xref></p>
        <p>Adrenoleukodystrophy gained recognition through the movie "Lorenzo's Oil." However, this mixture of oleic and erucic&#x000a0;triglycerides has not been proven effective in randomized controlled trials and is not approved by the US Food and Drug Administration (FDA). Bezafibrate and statin therapy have also been studied but have not yet been proven effective. Crossing the blood-brain barrier is a pharmacodynamic challenge.<xref ref-type="bibr" rid="article-17243.r3">[3]</xref></p>
        <p>A multicenter, open-label phase I trial using lentiviral vectors carrying the <italic toggle="yes">ABCD1</italic> gene is currently underway in China. So far, significant adverse events have not been noted.<xref ref-type="bibr" rid="article-17243.r19">[19]</xref>&#x000a0;Recent trials exploring docosahexaenoic acid use to induce peroxisome proliferation have yielded inconclusive results.<xref ref-type="bibr" rid="article-17243.r20">[20]</xref><xref ref-type="bibr" rid="article-17243.r21">[21]</xref>&#x000a0;</p>
        <p>Physical therapy, management of urologic complications, and vocational counseling are adjunctive treatments that help improve patients' overall functional status. Given the multiple organs affected and the diverse needs of patients with adrenoleukodystrophy, an interprofessional team approach is recommended. This healthcare team should include, at a minimum, endocrinologists, neurologists, geneticists, and psychologists.</p>
      </sec>
      <sec id="article-17243.s11" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of neonatal adrenoleukodystrophy is comprehensive and includes several other genetic syndromes that present with neurological signs and symptoms in the neonatal period. These conditions include&#x000a0;Angelman syndrome, Prader-Willi syndrome, Zellweger spectrum disorders (such as Zellweger syndrome, infantile Refsum disease, and rhizomelic chondrodysplasia punctata type 1), hypoxic-ischemic encephalopathy, metabolic disorders, and myotonic dystrophy.</p>
        <p>For X-linked adrenoleukodystrophy (X-ALD), differential diagnoses include conditions characterized by demyelination, such as acute disseminated encephalomyelitis and multiple sclerosis.</p>
      </sec>
      <sec id="article-17243.s12" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>The 2 below-mentioned ongoing clinical trials are actively recruiting participants to evaluate potential therapeutic interventions for adrenoleukodystrophy.</p>
        <list list-type="bullet">
          <list-item>
            <p>NCT03727555: This clinical trial investigates the use of the lentiviral vector TYF-ABCD1 to correct the defective <italic toggle="yes">ABCD1</italic> gene responsible for adrenoleukodystrophy symptoms.</p>
          </list-item>
          <list-item>
            <p>NCT03852498: This trial aims to assess the effects of autologous CD34+ HSCT on adrenoleukodystrophy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17243.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for neonatal adrenoleukodystrophy and most forms of X-ALD is generally poor. However, patients with adrenomyeloneuropathy can survive past age 65, although often with significant morbidity.<xref ref-type="bibr" rid="article-17243.r12">[12]</xref>&#x000a0;Treatment is usually limited to symptomatic supportive management. Replacement therapy is effective for patients with Addison disease, while HSCT may benefit asymptomatic patients identified through newborn screening or incidental imaging, as well as those with mild symptoms.&#x000a0;</p>
      </sec>
      <sec id="article-17243.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Patients with adrenomyeloneuropathy have significantly increased other comorbid conditions that have not been fully characterized yet. These include increased levels of pulmonary disease, liver disease, cerebrovascular disease, and cancer.<xref ref-type="bibr" rid="article-17243.r12">[12]</xref></p>
      </sec>
      <sec id="article-17243.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Adrenoleukodystrophy is a peroxisome disease that affects neonates with&#x000a0;neonatal&#x000a0;adrenoleukodystrophy and children and adults with X-ALD, involving multiple organs, commonly the&#x000a0;CNS and the adrenal glands. Patients and families must be educated about the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neonatal adrenoleukodystrophy is autosomal recessive.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>X-ALD is X-linked recessive and thus has a male predominance.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The clinical presentation of adrenoleukodystrophy varies, with neurological dysfunction (symptoms such as hypotonia, weakness, developmental regression, and cognitive disabilities) and adrenal insufficiency (symptoms&#x000a0;such as&#x000a0;hypotension, fatigue, and hypoglycemia) being the most common clinical manifestations.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diagnosis of adrenoleukodystrophy requires a detailed history, physical examination, and&#x000a0;diagnostic&#x000a0;modalities that&#x000a0;include VLCFA&#x000a0;measurement, brain MRI, and specific genetic testing.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Early identification of adrenoleukodystrophy cases&#x000a0;before neurologic involvement is crucial for implementing HSCT. While HSCT carries risks, it also has potential benefits and may improve prognosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Corticosteroid and mineralocorticoid replacement therapy and HSCT may benefit some patients.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clinical trials are ongoing to evaluate potential gene therapies for adrenoleukodystrophy. Crossing the blood-brain barrier remains a key pharmacodynamic challenge.</p>
          </list-item>
        </list>
        <p>Genetic testing is imperative for properly counseling female carriers and patients' families. Affected families should be educated to&#x000a0;help them understand the risks of transmission, consider prenatal testing or preimplantation genetic diagnosis, and make informed decisions regarding reproductive choices.</p>
      </sec>
      <sec id="article-17243.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Providing patient-centered care for individuals with adrenoleukodystrophy requires a collaborative effort among healthcare professionals, including physicians, advanced practice practitioners, nurses, and pharmacists. Healthcare providers must possess the necessary clinical skills and expertise in diagnosing, evaluating, and treating this condition. This includes proficiency in interpreting genetic testing, recognizing potential complications, and understanding the nuances of disease progression.&#x000a0;</p>
        <p>An interprofessional healthcare team consisting of neurologists, endocrinologists, geneticists, dieticians, and psychologists is recommended to provide comprehensive care to individuals with adrenoleukodystrophy.&#x000a0;This collaborative approach should address both the medical and psychosocial aspects of living with adrenoleukodystrophy. Moreover, a strategic approach involving evidence-based guidelines and individualized care plans tailored to each patient's unique circumstances is vital.</p>
        <p>Ethical considerations are crucial when determining treatment options and respecting patient autonomy in shared decision-making. Responsibilities within the interprofessional team should be clearly defined, with each member contributing their specialized knowledge and skills to optimize patient care. Effective interprofessional communication fosters a collaborative environment where information is shared, questions are encouraged, and concerns are addressed promptly.</p>
        <p>Lastly, care coordination is pivotal in ensuring seamless and efficient patient care. Physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals must collaborate to streamline the patient&#x02019;s journey from diagnosis through treatment and follow-up. This coordination helps minimize errors, reduce delays, and enhance patient safety, ultimately leading to improved outcomes and patient-centered care that prioritizes the well-being and satisfaction of those affected by adrenoleukodystrophy.</p>
      </sec>
      <sec id="article-17243.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17243&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17243">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/adrenoleukodystrophy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17243">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17243/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17243">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17243.s18">
        <title>References</title>
        <ref id="article-17243.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engelen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Visser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Geel</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Wanders</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Aubourg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Poll-The</surname>
                <given-names>BT</given-names>
              </name>
            </person-group>
            <article-title>X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2012</year>
            <month>Aug</month>
            <day>13</day>
            <volume>7</volume>
            <fpage>51</fpage>
            <pub-id pub-id-type="pmid">22889154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mares Beltran</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Tise</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Barrick</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Niehaus</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Sponberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Enns</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Abdenur</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Newborn Screening for X-Linked Adrenoleukodystrophy (X-ALD): Biochemical, Molecular, and Clinical Characteristics of Other Genetic Conditions.</article-title>
            <source>Genes (Basel)</source>
            <year>2024</year>
            <month>Jun</month>
            <day>26</day>
            <volume>15</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">39062617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turk</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Theda</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fatemi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies.</article-title>
            <source>Int J Dev Neurosci</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <page-range>52-72</page-range>
            <pub-id pub-id-type="pmid">31909500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Genchev</surname>
                <given-names>GZ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sriswasdi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Multivariate analysis and model building for classifying patients in the peroxisomal disorders X-linked adrenoleukodystrophy and Zellweger syndrome in Chinese pediatric patients.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2023</year>
            <month>May</month>
            <day>02</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <pub-id pub-id-type="pmid">37189159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonkowsky</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wilkes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bardsley</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Urbik</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Stoddard</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Association of Diagnosis of Leukodystrophy With Race and Ethnicity Among Pediatric and Adolescent Patients.</article-title>
            <source>JAMA Netw Open</source>
            <year>2018</year>
            <month>Nov</month>
            <day>02</day>
            <volume>1</volume>
            <issue>7</issue>
            <fpage>e185031</fpage>
            <pub-id pub-id-type="pmid">30646379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Steinberg</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Raymond</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Braverman</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <chapter-title>Zellweger Spectrum Disorder</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2003</year>
            <month>12</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">20301621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eichler</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Biffi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Majzoub</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The Changing Face of Adrenoleukodystrophy.</article-title>
            <source>Endocr Rev</source>
            <year>2020</year>
            <month>Aug</month>
            <day>01</day>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>577</fpage>
            <page-range>577-93</page-range>
            <pub-id pub-id-type="pmid">32364223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parasar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of X-Linked Adrenoleukodystrophy: Updates on Molecular Mechanisms.</article-title>
            <source>J Biotechnol Biomed</source>
            <year>2024</year>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>277</fpage>
            <page-range>277-288</page-range>
            <pub-id pub-id-type="pmid">39056013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ulrich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Herschkowitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Heitz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sigrist</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baerlocher</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Adrenoleukodystrophy. Preliminary report of a connatal case. Light- and electron microscopical, immunohistochemical and biochemical findings.</article-title>
            <source>Acta Neuropathol</source>
            <year>1978</year>
            <month>Aug</month>
            <day>07</day>
            <volume>43</volume>
            <issue>1-2</issue>
            <fpage>77</fpage>
            <page-range>77-83</page-range>
            <pub-id pub-id-type="pmid">209659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powers</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications.</article-title>
            <source>J Neuropathol Exp Neurol</source>
            <year>1992</year>
            <month>Nov</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>630</fpage>
            <page-range>630-43</page-range>
            <pub-id pub-id-type="pmid">1362438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farrell</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Neonatal adrenoleukodystrophy: a clinical, pathologic, and biochemical study.</article-title>
            <source>Pediatr Neurol</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>330</fpage>
            <page-range>330-6</page-range>
            <pub-id pub-id-type="pmid">23044013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonkowsky</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Healey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sacks</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>McLin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cyr</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Sawyer</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Stephen</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Eichler</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Burden of illness and mortality in men with Adrenomyeloneuropathy: a retrospective cohort study.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2024</year>
            <month>Jul</month>
            <day>17</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>270</fpage>
            <pub-id pub-id-type="pmid">39020416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engelen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barbier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dijkstra</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Sch&#x000fc;r</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Bie</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Verhamme</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dijkgraaf</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Aubourg</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Wanders</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van Geel</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>de Visser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poll-The</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>X-linked adrenoleukodystrophy in women: a cross-sectional cohort study.</article-title>
            <source>Brain</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>137</volume>
            <issue>Pt 3</issue>
            <fpage>693</fpage>
            <page-range>693-706</page-range>
            <pub-id pub-id-type="pmid">24480483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gujral</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sethuram</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>An update on the diagnosis and treatment of adrenoleukodystrophy.</article-title>
            <source>Curr Opin Endocrinol Diabetes Obes</source>
            <year>2023</year>
            <month>Feb</month>
            <day>01</day>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-51</page-range>
            <pub-id pub-id-type="pmid">36373727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stradomska</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Syczewska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jamroz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pleskaczy&#x00144;ska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kruczek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ciara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tylki-Szymanska</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Serum very long-chain fatty acids (VLCFA) levels as predictive biomarkers of diseases severity and probability of survival in peroxisomal disorders.</article-title>
            <source>PLoS One</source>
            <year>2020</year>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>e0238796</fpage>
            <pub-id pub-id-type="pmid">32946460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molzer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kainz-Korschinsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sundt-Heller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bernheimer</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Phytanic acid and very long chain fatty acids in genetic peroxisomal disorders.</article-title>
            <source>J Clin Chem Clin Biochem</source>
            <year>1989</year>
            <month>May</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>309</fpage>
            <page-range>309-14</page-range>
            <pub-id pub-id-type="pmid">2474624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boehm</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Cutting</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Lachtermacher</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy.</article-title>
            <source>Mol Genet Metab</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>66</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-36</page-range>
            <pub-id pub-id-type="pmid">10068516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eichler</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Musolino</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Orchard</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>De Oliveira</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thrasher</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Armant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dansereau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Raymond</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Sankar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sevin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gaspar</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Gissen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Amartino</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bratkovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>NJC</given-names>
              </name>
              <name>
                <surname>Paker</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shamir</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>O'Meara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aubourg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Oct</month>
            <day>26</day>
            <volume>377</volume>
            <issue>17</issue>
            <fpage>1630</fpage>
            <page-range>1630-1638</page-range>
            <pub-id pub-id-type="pmid">28976817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>QH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>ZP</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>ZQ</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>Phase I clinical trial of intracerebral injection of lentiviral-ABCD1 for the treatment of cerebral adrenoleukodystrophy.</article-title>
            <source>Sci Bull (Beijing)</source>
            <year>2024</year>
            <month>Aug</month>
            <day>30</day>
            <volume>69</volume>
            <issue>16</issue>
            <fpage>2596</fpage>
            <page-range>2596-2603</page-range>
            <pub-id pub-id-type="pmid">39025777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinez</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Restoring the DHA levels in the brains of Zellweger patients.</article-title>
            <source>J Mol Neurosci</source>
            <year>2001</year>
            <season>Apr-Jun</season>
            <volume>16</volume>
            <issue>2-3</issue>
            <fpage>309</fpage>
            <page-range>309-16; discussion 317-21</page-range>
            <pub-id pub-id-type="pmid">11478386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17243.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McGuinness</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological induction of peroxisomes in peroxisome biogenesis disorders.</article-title>
            <source>Ann Neurol</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>286</fpage>
            <page-range>286-96</page-range>
            <pub-id pub-id-type="pmid">10716247</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
